Achaogen, Inc. (AKAO) COO Sells $57,180.24 in Stock
Achaogen, Inc. (NASDAQ:AKAO) COO Blake Wise sold 3,576 shares of the business’s stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $15.99, for a total transaction of $57,180.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Achaogen, Inc. (NASDAQ AKAO) opened at 15.95 on Friday. Achaogen, Inc. has a 52 week low of $3.68 and a 52 week high of $27.79. The firm’s market capitalization is $673.62 million. The company has a 50-day moving average of $17.84 and a 200-day moving average of $21.63.
Achaogen (NASDAQ:AKAO) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.18). The company had revenue of $1.30 million during the quarter, compared to analyst estimates of $2.69 million. Achaogen had a negative return on equity of 86.24% and a negative net margin of 281.88%. The company’s revenue for the quarter was down 85.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.87) earnings per share. On average, equities analysts forecast that Achaogen, Inc. will post ($3.04) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Achaogen, Inc. (AKAO) COO Sells $57,180.24 in Stock” was published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.watchlistnews.com/achaogen-inc-akao-coo-sells-57180-24-in-stock/1600749.html.
Several equities analysts have recently issued reports on the stock. Mizuho reissued a “buy” rating and issued a $28.00 price target on shares of Achaogen in a report on Thursday. BidaskClub lowered shares of Achaogen from a “sell” rating to a “strong sell” rating in a report on Saturday, August 12th. Stifel Nicolaus reissued a “buy” rating and issued a $30.00 price target on shares of Achaogen in a report on Friday, August 4th. Zacks Investment Research raised shares of Achaogen from a “sell” rating to a “hold” rating and set a $27.00 price target for the company in a report on Monday, July 17th. Finally, HC Wainwright assumed coverage on shares of Achaogen in a report on Thursday, June 15th. They issued a “buy” rating and a $29.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Achaogen currently has a consensus rating of “Buy” and a consensus price target of $27.68.
A number of large investors have recently bought and sold shares of AKAO. Bank of Montreal Can grew its holdings in Achaogen by 25.0% in the first quarter. Bank of Montreal Can now owns 7,500 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 1,500 shares during the period. Bank of New York Mellon Corp grew its holdings in Achaogen by 2.8% in the first quarter. Bank of New York Mellon Corp now owns 113,783 shares of the biopharmaceutical company’s stock worth $2,871,000 after purchasing an additional 3,150 shares during the period. TD Asset Management Inc. acquired a new stake in Achaogen in the first quarter worth $1,217,000. Parametric Portfolio Associates LLC grew its holdings in Achaogen by 119.1% in the first quarter. Parametric Portfolio Associates LLC now owns 51,359 shares of the biopharmaceutical company’s stock worth $1,296,000 after purchasing an additional 27,914 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in Achaogen in the first quarter worth $1,114,000. Institutional investors and hedge funds own 84.12% of the company’s stock.
Achaogen Company Profile
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.